Patents by Inventor Robert Frank Roscigno
Robert Frank Roscigno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346799Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 12, 2023Publication date: November 2, 2023Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744835Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744836Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11712442Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: November 25, 2020Date of Patent: August 1, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11660304Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: April 13, 2022Date of Patent: May 30, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20220257608Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: April 13, 2022Publication date: August 18, 2022Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210353641Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210353640Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210077504Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 10898494Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: May 5, 2017Date of Patent: January 26, 2021Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20190151332Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: May 5, 2017Publication date: May 23, 2019Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor